199 related articles for article (PubMed ID: 24471314)
1. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
[TBL] [Abstract][Full Text] [Related]
2. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of rational clinical uses of traditional Chinese medicine injections and factors influencing adverse drug reactions].
Sun SG; Li ZF; Xie YM; Liu J; Lu Y; Song YF; Han YH; Liu LD; Peng TT
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2969-73. PubMed ID: 24471313
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
[TBL] [Abstract][Full Text] [Related]
5. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
Zhang W; Xie YM; Yu WY
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
[TBL] [Abstract][Full Text] [Related]
6. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
7. [Enlightenment of adverse reaction monitoring on safety evaluation of traditional Chinese medicines].
Song HB; Du XX; Ren JT; Yang L; Guo XX; Pang Y
Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1620-3. PubMed ID: 26281610
[TBL] [Abstract][Full Text] [Related]
8. [Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].
Xie YM; Zhao YB; Jiang JJ; Chang YP; Zhang W; Shen H; Lu PF
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2933-6. PubMed ID: 24471307
[TBL] [Abstract][Full Text] [Related]
9. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine].
Yan BH; Peng C; Xie YM; Wang YY
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315
[TBL] [Abstract][Full Text] [Related]
10. [Necessity of applying pharmacovigilance in post-marketing safety monitoring of traditional Chinese medicine injections].
Wang HN; Chen W; Fu Z; Du WM; He J
Zhongguo Zhong Yao Za Zhi; 2008 Mar; 33(5):612-4. PubMed ID: 18536393
[TBL] [Abstract][Full Text] [Related]
11. [Research progress of adverse reactions of traditional Chinese medicine injections].
Tan LJ; Wang M; Zhu Y
Zhongguo Zhong Yao Za Zhi; 2014 Oct; 39(20):3889-98. PubMed ID: 25751935
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2786-8. PubMed ID: 22292365
[TBL] [Abstract][Full Text] [Related]
13. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
[TBL] [Abstract][Full Text] [Related]
14. [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine].
Zheng WK; Liu Z; Lei X; Tian R; Zheng R; Li N; Ren JT; Du XX; Shang HC
Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3693-6. PubMed ID: 26983223
[TBL] [Abstract][Full Text] [Related]
15. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
Kou Q; Zhao S; Feng G; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
[TBL] [Abstract][Full Text] [Related]
16. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
[TBL] [Abstract][Full Text] [Related]
17. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
Ai QH; Li YY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
[TBL] [Abstract][Full Text] [Related]
18. [Interpretation of contemporary positioning of traditional Chinese medicine injections and analysis of key problems].
Gao F; Leng J; Fu CM; Zhang JM; Liao W; Hu HL; He Y; Gan YX; Hao L
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3416-9. PubMed ID: 25522642
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective.
Zhang L; Yan J; Liu X; Ye Z; Yang X; Meyboom R; Chan K; Shaw D; Duez P
J Ethnopharmacol; 2012 Apr; 140(3):519-25. PubMed ID: 22374080
[TBL] [Abstract][Full Text] [Related]
20. [Development of quality traceability system of traditional Chinese medicine].
Cai Y; Hu H; Ni JY; Wang YT
Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(22):3829-33. PubMed ID: 24558859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
